New hope for liver disease patients unresponsive to standard drugs
Disease control
Completed
This study tested a new medicine called CNP-104 in 42 adults aged 18-75 with primary biliary cholangitis, a chronic liver disease. Participants were not helped enough by standard treatments. The goal was to check if CNP-104 is safe and can control the disease. The study lasted ab…
Phase: PHASE1, PHASE2 • Sponsor: COUR Pharmaceutical Development Company, Inc. • Aim: Disease control
Last updated Apr 26, 2026 19:38 UTC